Matsuo-Tani, A.; Matsumoto, M.; Hiu, T.; Kamiya, M.; Geng, L.; Takayama, R.; Ushiroda, Y.; Kato, N.; Nakamura, H.; Yoshida, M.;
et al. Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles. Pharmaceutics 2025, 17, 1298.
https://doi.org/10.3390/pharmaceutics17101298
AMA Style
Matsuo-Tani A, Matsumoto M, Hiu T, Kamiya M, Geng L, Takayama R, Ushiroda Y, Kato N, Nakamura H, Yoshida M,
et al. Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles. Pharmaceutics. 2025; 17(10):1298.
https://doi.org/10.3390/pharmaceutics17101298
Chicago/Turabian Style
Matsuo-Tani, Ayaka, Makoto Matsumoto, Takeshi Hiu, Mariko Kamiya, Longjian Geng, Riku Takayama, Yusuke Ushiroda, Naoya Kato, Hikaru Nakamura, Michiharu Yoshida,
and et al. 2025. "Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles" Pharmaceutics 17, no. 10: 1298.
https://doi.org/10.3390/pharmaceutics17101298
APA Style
Matsuo-Tani, A., Matsumoto, M., Hiu, T., Kamiya, M., Geng, L., Takayama, R., Ushiroda, Y., Kato, N., Nakamura, H., Yoshida, M., Mukai, H., Matsuo, T., & Kawakami, S.
(2025). Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles. Pharmaceutics, 17(10), 1298.
https://doi.org/10.3390/pharmaceutics17101298
